NRG1 and non-small cell lung carcinoma: CRESTONE trial (NCT04383210) interim analysis in 2022 showed a 90% disease control rate of seribantumab (CR = 1, PR = 2, SD = 6, PD = 1) in ten NSCLC patients with five different NRG1 fusion partners (ATP1B1, CD74, ITGB1, SDC4, SLC3A2).